DarioHealth (Nasdaq:DRIO) announced today that a new analysis demonstrated a significant cost reudction for users of its digital therapeutic platform.
Sanofi U.S. conducted the analysis, which showed lower costs of care for DarioHealth users compared to non-users with type 2 diabetes. The study used matched claims to show an estimated $5,077 in medical cost savings for the DarioHealth users.
This new data came from an exact match and propensity-score matched non-user cohort. It included access to usual care in a cohort of 2,445 DarioHealth users and 7,334 matched non-users. Cost-to-charge ratios determined potential paid savings in costs of care across both inpatient and outpatient care.
“Digital health historically lacks the rigorous research needed to help payers assess value, and our partners at Sanofi are charting a new standard with this robust, arms-length analysis of Dario user data,” said Dr. Omar Manejwala, chief medical officer of DarioHealth. “We are incredibly proud to share this new data resulting from a rigorous well matched study design to offer the credible evidence of cost savings our partners demand.”
The study came under DarioHealth’s collaboration with Sanofi aimed at setting new standards in digital health. The companies want to analyze real-world digital health data using the evidence generation principles of a pharmaceutical study.
“Our studies have shown not only the effectiveness and safety of a digital health intervention, but also how this can save spending for health systems,” said Felix Lee, medical head of digital healthcare, Sanofi U.S. “Digital health has the potential to address gaps in chronic care in addition to usual pharmaceutical care to improve clinical and economic outcomes and we are excited to be innovating in how best to showcase these benefits.”
